TY - JOUR
T1 - Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia
T2 - Challenging its predictive value
AU - Ruggeri, Loredana
AU - Mancusi, Antonella
AU - Capanni, Marusca
AU - Urbani, Elena
AU - Carotti, Alessandra
AU - Aloisi, Teresa
AU - Stern, Martin
AU - Pende, Daniela
AU - Perruccio, Katia
AU - Burchielli, Emanuela
AU - Topini, Fabiana
AU - Bianchi, Erika
AU - Aversa, Franco
AU - Martelli, Massimo F.
AU - Velardi, Andrea
PY - 2007/7/1
Y1 - 2007/7/1
N2 - We analyzed 112 patients with high-risk acute myeloid leukemia (61 in complete remission [CR]; 51 in relapse), who received human leukocyte-antigen (HLA)-haploidentical transplants from natural killer (NK) alloreactive (n = 51) or non-NK alloreactive donors (n = 61). NK alloreactive donors possessed HLA class I, killercell immunoglobulin-like receptor (KIR) ligand(s) which were missing in the recipients, KIR gene(s) for missing self recognition on recipient targets, and alloreactive NK clones against recipient targets. Transplantation from NK-alloreactive donors was associated with a significantly lower relapse rate in patients transplanted in CR (3% versus 47%) (P > .003), better event-free survival in patients transplanted in relapse (34% versus 6%, P = .04) and in remission (67% versus 18%, P = .02), and reduced risk of relapse or death (relative risk versus non-NK-alloreactive donor, 0.48; 95% CI, 0.29-0.78; P > .001). In all patients we tested the "missing ligand" model which pools KIR ligand mismatched transplants and KIR ligand-matched transplants from donors possessing KIR(s) for which neither donor nor recipient have HLA ligand(s). Only transplantation from NK-alloreactive donors is associated with a survival advantage.
AB - We analyzed 112 patients with high-risk acute myeloid leukemia (61 in complete remission [CR]; 51 in relapse), who received human leukocyte-antigen (HLA)-haploidentical transplants from natural killer (NK) alloreactive (n = 51) or non-NK alloreactive donors (n = 61). NK alloreactive donors possessed HLA class I, killercell immunoglobulin-like receptor (KIR) ligand(s) which were missing in the recipients, KIR gene(s) for missing self recognition on recipient targets, and alloreactive NK clones against recipient targets. Transplantation from NK-alloreactive donors was associated with a significantly lower relapse rate in patients transplanted in CR (3% versus 47%) (P > .003), better event-free survival in patients transplanted in relapse (34% versus 6%, P = .04) and in remission (67% versus 18%, P = .02), and reduced risk of relapse or death (relative risk versus non-NK-alloreactive donor, 0.48; 95% CI, 0.29-0.78; P > .001). In all patients we tested the "missing ligand" model which pools KIR ligand mismatched transplants and KIR ligand-matched transplants from donors possessing KIR(s) for which neither donor nor recipient have HLA ligand(s). Only transplantation from NK-alloreactive donors is associated with a survival advantage.
UR - http://www.scopus.com/inward/record.url?scp=34347396957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347396957&partnerID=8YFLogxK
U2 - 10.1182/blood-2006-07-038687
DO - 10.1182/blood-2006-07-038687
M3 - Article
C2 - 17371948
AN - SCOPUS:34347396957
SN - 0006-4971
VL - 110
SP - 433
EP - 440
JO - Blood
JF - Blood
IS - 1
ER -